Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44236   clinical trials with a EudraCT protocol, of which   7337   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-003213-34
    Sponsor's Protocol Code Number:270-205
    National Competent Authority:UK - MHRA
    Clinical Trial Type:EEA CTA
    Trial Status:GB - no longer in EU/EEA
    Date on which this record was first entered in the EudraCT database:2020-03-17
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedUK - MHRA
    A.2EudraCT number2019-003213-34
    A.3Full title of the trial
    A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Active or Prior Inhibitors
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 1/2 study to evaluate the safety and efficacy of BMN 270 gene transfer in patients with severe hemophilia A and active or prior inhibitors
    A.4.1Sponsor's protocol code number270-205
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBioMarin Pharmaceutical Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBioMarin Pharmaceutical Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBioMarin Pharmaceutical Inc.
    B.5.2Functional name of contact pointClinical Trials Information
    B.5.3 Address:
    B.5.3.1Street Address105 Digital Drive
    B.5.3.2Town/ cityNovato
    B.5.3.3Post code94949
    B.5.3.4CountryUnited States
    B.5.6E-mailmedinfo@bmrn.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/16/1622
    D.3 Description of the IMP
    D.3.1Product nameAAV5-hFVIII-SQ
    D.3.2Product code BMN 270
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNValoctocogene roxaparvovec
    D.3.9.1CAS number 1819334-78-5
    D.3.9.2Current sponsor codeBMN 270
    D.3.9.3Other descriptive nameAAV5-hFVIII-SQ
    D.3.9.4EV Substance CodeSUB198084
    D.3.10 Strength
    D.3.10.1Concentration unit vector genomes (vg)/mL
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2E13
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Yes
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product Yes
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms Yes
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Hemophilia A
    E.1.1.1Medical condition in easily understood language
    Bleeding Disorder
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10060612
    E.1.2Term Hemophilia A
    E.1.2System Organ Class 100000004850
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the safety of a single IV administration of BMN 270 in HA subjects with active inhibitors (Part A), or prior inhibitors (Part B)
    E.2.2Secondary objectives of the trial
    - To assess the efficacy of BMN 270 as measured by FVIII activity together with the level of inhibitor titer (Part A) and the recurrence of inhibitors (Part B)
    - To assess the impact of BMN 270 on the use of emicizumab (Part A) and FVIII prophylaxis (Part B)
    - To assess the impact of BMN 270 on the number of bleeding episodes requiring pharmacologic intervention
    - To assess the impact of BMN 270 on quality of life as measured by the Haemo-QoL-A questionnaire
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Males ≥ 18 years of age with hemophilia A and documented prior residual FVIII activity ≤ 1 IU/dL including, but not limited to, at the time of detected inhibitors, at the time of signing the informed consent.
    2. Documented history of a prior positive inhibitor result (results from a Bethesda Assay or Nijmegen Bethesda Assay ≥ 0.6 BU), with the first detection of the inhibitor at least 12 months prior to Screening.
    For Part A: Positive FVIII inhibitor test per central lab at Screening, defined as inhibitor titer ≥ 0.6 BU from the chromogenic Nijmegen-Bethesda Assay (cNBA). The first 3 subjects enrolled in Part A must have an inhibitor titer ≥ 5 BU.
    For Part B: Negative FVIII inhibitor test per central lab at Screening, defined as inhibitor titer < 0.6 BU from cNBA.
    3. For Part A: Subject must be on emicizumab prophylaxis for at least 6 months prior to Screening. Subjects are required to be taking emicizumab at a maintenance dose of 1.5 mg/kg weekly, or be willing to switch to this regimen, prior to dosing with BMN 270. High quality, well-documented historical data concerning bleeding episodes, inhibitor history, and hemophilia therapy over the previous 12 months must be available.
    For Part B: Subject must be on FVIII replacement prophylaxis therapy for at least
    12 months prior to Screening. High quality, well-documented historical data concerning bleeding episodes, inhibitor history, and hemophilia therapy over the previous 12 months must be available.
    4. Willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to any study-related procedures.
    5. Sexually active participants must agree to use an acceptable method of effective contraception, either double-barrier contraception (ie, condom + diaphragm; or condom or diaphragm + spermicidal gel or foam) or their female partner either using hormonal contraceptives or having an intrauterine device. Participants must agree to contraception use for at least 12 weeks post-infusion; after 12 weeks, subjects may stop contraception use only if they have had 3 consecutive semen samples with viral vector DNA below the limit of detection.
    6. Willing to abstain from consumption of alcohol for at least the first 52 weeks following BMN 270 infusion.
    E.4Principal exclusion criteria
    1. Detectable pre-existing antibodies to the AAV5 capsid.
    2. Any evidence of active infection, including COVID-19, or any immunosuppressive disorder, including HIV infection.
    3. Currently undergoing, or plan to receive during the study, immune tolerance induction therapy or prophylaxis with FVIII (Part A only).
    4. Significant liver dysfunction with any of the following abnormal laboratory results:
    a. ALT (alanine aminotransferase) > 1.25x ULN;
    b. AST (aspartate aminotransferase) > 1.25x ULN;
    c. GGT (gamma-glutamyltransferase) > 1.25x ULN;
    d. Total bilirubin > 1.25x ULN;
    e. Alkaline phosphatase > 1.25x ULN; or
    f. INR (international normalized ratio) ≥ 1.4
    Subjects whose liver laboratory assessments fall outside of these ranges may undergo repeat testing of the entire liver test panel within the same Screening window and, if eligibility criteria are met on retest, may be enrolled after confirmation by the Medical Monitor.
    5. Most recent, prior FibroScan or prior liver biopsy showing significant fibrosis of 3 or
    4 as rated on a scale of 0-4 on the Batts-Ludwig (Batts 1995) or METAVIR (Bedossa 1996) scoring systems, or an equivalent grade of fibrosis if an alternative scale is used.
    6. Evidence of any bleeding disorder not related to hemophilia A.
    7. Platelet count of < 100 x 109/L.
    8. Significant renal dysfunction with any of the following abnormal laboratory results:
    a. serum creatinine >1.5 mg/dL
    b. estimated glomerular filtration rate (eGFR) <90 mL/min/1.73m2 by the Modification of Diet
    in Renal Disease (MDRD) equation
    c. hematuria or proteinuria as indicated by urine dipstick test at screening.
    9. Liver cirrhosis of any etiology as assessed by liver ultrasound/FibroScan.
    10. Chronic or active hepatitis B as evidenced by positive serology testing (hepatitis B surface antigen [HBsAg], hepatitis B surface antibody [HBsAb], and hepatitis B core antibody [HBcAb]) and confirmatory HBV DNA testing. Refer to the Centers for Disease Control (CDC) table for the interpretation of serological test results.
    11. Active Hepatitis C as evidenced by detectable HCV RNA, or currently on antiviral therapy.
    12. Active malignancy, except non-melanoma skin cancer.
    13. History of hepatic malignancy.
    14. History of arterial or venous thromboembolic events (eg, deep vein thrombosis, non-hemorrhagic stroke, pulmonary embolism, myocardial infarction, arterial embolus), except for catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing.
    15. Known inherited or acquired thrombophilia, including conditions associated with increased thromboembolic risk, such as atrial fibrillation.
    16. A history of known inflammatory, connective tissue, or autoimmune disorders (eg, vasculitis).
    17. Treatment with any Investigational Product within 30 days or 5 half-lives of the investigational product (whichever is longer) prior to the screening period. For subjects who have received a prior investigational product, all ongoing adverse events (AEs) experienced while receiving that investigational product must have resolved prior to screening for this study.
    18. Any condition that, in the opinion of the investigator or Sponsor would prevent the patient from fully complying with the requirements of the study (including corticosteroid treatment and/or use of alternative immunosuppressive agents outlined in the protocol) and/or would impact or interfere with evaluation and interpretation of subject safety or efficacy result.
    19. Prior treatment with any vector or gene transfer agent.
    20. Major surgery planned in the 26-week period following the infusion with BMN 270.
    21. Use of systemic immunosuppressive agents, not including corticosteroids, or live vaccines within 30 days before the BMN 270 infusion.
    22. Concurrent enrollment in another clinical study, unless it is an observational
    (non-interventional) clinical study that does not interfere with the requirements of the current protocol or have the potential to impact the evaluation of safety and efficacy of BMN 270 and with prior consultation with the Medical Monitor.
    23. Known allergy or hypersensitivity to investigational product formulation.
    24. Unwilling to receive blood or blood products for treatment of an adverse event and/or a bleed.
    E.5 End points
    E.5.1Primary end point(s)
    •FVIII inhibitors
    •Incident of AEs and SAEs
    •Change in clinical laboratory tests (serum chemistry and hematology)
    •Change in vital signs
    •Change in physical examination
    •Vector shedding (blood, urine, semen, stool, saliva)
    •Liver tests (LTs, including ALT, AST, GGT, LDH, total bilirubin, and alkaline phosphatase)
    •Immune responses to AAV5 capsid proteins
    •Immunological assessments, including hFVIII TAb, IFN ELISpot, PBMC for exploratory immunogenicity assessments, a complement panel (C3, C3a, C4, Bb, and sC5b-9), and an exploratory biomarker panel.
    E.5.1.1Timepoint(s) of evaluation of this end point
    •cNBA for FVIII inhibitor level; Throughout the weeks 1-52 and then q4w on Year 2 and q6w on Year 3-5
    •Adverse events; Day 8, then throughout the weeks 2-52 and then q4w on Year 2 and q6w on Year 3-5
    •Vital Signs; Day 8 and then throughout the weeks 2-52 and then q12w
    •Physical examination; Throughout the weeks 4-52 and then q12w
    •Clinical laboratory tests; Throughout the weeks 2-52 and then q12w
    •Vector shedding; Day 8 and then throughout the weeks 4-52 and then q12w
    •Liver tests; Day 2, 4 and 8, and then throughout the weeks 2-52 and then q4w on Year 2 and q6w on Year 3-5
    •Immune response to AAV5 capsid proteins; Throughout the weeks 4-52 and then annually until the study end
    •Immunological assessments; Throughout the weeks 2-52 then q24w and at End of Year visits
    E.5.2Secondary end point(s)
    •hFVIII activity
    •Decrease in anti-FVIII inhibitory titer post infusion (Part A)
    •Absence of anti-FVIII inhibitors (Part B)
    •Change in the annualized utilization of emicizumab post-BMN 270 infusion from the baseline utilization of emicizumab (Part A)
    •Change in the annualized utilization (IU/kg) of exogenous FVIII replacement therapy post-BMN 270 infusion from the baseline utilization of exogenous FVIII replacement therapy (Part B)
    •Change in the annualized number of bleeding episodes requiring treatment (annualized bleeding rate, ABR) post-BMN 270 infusion from the baseline ABR
    •Change from baseline on quality of life as measured by Haemo-QoL-A questionnaire
    E.5.2.1Timepoint(s) of evaluation of this end point
    • Measured FVIII concentration/activity will be used for plasma profiles to determine PD parameters.
    • cNBA for hFVIII inhibitor level; Part A: Day 4 and 8, weeks 2-26 then per the protocol schedule q2w or q4w or q6w and Part B: Weeks 1-26 then per the protocol schedule q2w or q4w, or q6w
    • Change in utilization of emicizumab (Part A); Day 8, Weeks 2-26, then per the protocol schedule q2w or q4w or q6w
    • Change in utilization of exogenous FVIII replacement therapy (Part B); Day 8, Weeks 2-26, then per the protocol schedule q2w or q4w or q6w
    • Change in bleeding episodes; Throughout the study every week
    • Impact of BMN 270 on quality of life as measured by the Haemo-QoL-A questionnaire; throughout the weeks 4-52 and then q12w
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA7
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    France
    Germany
    Italy
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 17
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 3
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 12
    F.4.2.2In the whole clinical trial 20
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-04-15
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-09-25
    P. End of Trial
    P.End of Trial StatusGB - no longer in EU/EEA
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA